Pemafibrate is associated with greater reductions in MDA-LDL and small dense LDL fractions with exploratory PBMC gene-expression changes: a prespecified subanalysis of the PARADISE in Kagoshima study
Frontiers in Clinical Diabetes and Healthcare · 01.07.2026 · 7
DOI: 10.3389/fcdhc.2026.1850470 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Clinical Diabetes and Healthcare, online erschienen am 01.07.2026. Verfasst von Toru Kubo und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diabetes and Endocrine Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Pemafibrate, a selective peroxisome proliferator-activated receptor alpha (PPARα) modulator, lowers triglycerides and improves lipid parameters. However, its effects on oxidized LDL-related markers, including malondialdehyde-modified low-density lipoprotein (MDA-LDL), and associated in vivo gene-expression changes in humans remain limited. In addition, whether pemafibrate-associated changes in oxidized LDL-related biomarkers have clinical implications for atherosclerotic progression or cardiovascular risk remains uncertain.
Methods
In this prespecified subanalysis of the randomized, open-label, parallel-group PARADISE in Kagoshima study, 51 participants assigned to pemafibrate and 46 assigned to eicosapentaenoic acid (EPA) were included in the clinical analysis. All participants had type 2 diabetes and hypertriglyceridemia and received treatment for 16 weeks. We evaluated changes in MDA-LDL, lipoprotein fractions including small dense LDL-related fractions, and exploratory peripheral blood mononuclear cell (PBMC) gene expression. PBMC gene expression was assessed in 11 participants in the Pemafibrate group and 7 in the EPA group, and was considered exploratory and hypothesis-generating.
Results
Compared with EPA, pemafibrate produced a significantly greater reduction in triglycerides (least-squares mean difference, −79.2 mg/dL; 95% confidence interval [CI], −117 to −41.5; P < 0.001), and a greater increase in HDL-C (4.64 mg/dL; 95% CI, 2.43 to 6.84; P < 0.001). The mean change in MDA-LDL from baseline to week 16 was −30.3 ± 32.4 U/L in the Pemafibrate group and −9.2 ± 44.3 U/L in the EPA group, yielding a least-squares mean difference of −21.2 U/L (95% CI, −36.9 to −5.4; P = 0.009). In the exploratory PBMC analysis, ABCA1 and LCAT remained significant after false discovery rate adjustment, whereas other genes showed only nominal differences.
Conclusion
Pemafibrate was associated with greater 16-week reductions in MDA-LDL and small dense LDL fractions than EPA in patients with type 2 diabetes and hypertriglyceridemia. These findings suggest modification of selected lipid-quality biomarkers. Their clinical relevance remains to be established.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Diabetes and Endocrine Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.
- Department of Medicine, Izuro Imamura Hospital, Kagoshima, Japan.
- Hayato Medical Clinic, Kirishima, Japan.
- Gyokusuikai Hospital, Kagoshima, Japan.
- National Hospital Organization Kagoshima Medical Center, Kagoshima, Japan.
Zitieren
APA
Kubo, T., Deguchi, T., Matsuzaki, K., Shinnakasu, A., Kawade, S., Arimura, A., Hashiguchi, H., Ogiso, K., Kamada, T., Kurano, M., Morino, K., & Nishio, Y. (2026). Pemafibrate is associated with greater reductions in MDA-LDL and small dense LDL fractions with exploratory PBMC gene-expression changes: a prespecified subanalysis of the PARADISE in Kagoshima study. Frontiers in Clinical Diabetes and Healthcare, 7. https://doi.org/10.3389/fcdhc.2026.1850470
Vancouver
Kubo T, Deguchi T, Matsuzaki K, Shinnakasu A, Kawade S, Arimura A, et al. Pemafibrate is associated with greater reductions in MDA-LDL and small dense LDL fractions with exploratory PBMC gene-expression changes: a prespecified subanalysis of the PARADISE in Kagoshima study. Frontiers in Clinical Diabetes and Healthcare. 2026;7. doi:10.3389/fcdhc.2026.1850470
BibTeX
@article{Kubo2026,
author = {Kubo, Toru and Deguchi, Takahisa and Matsuzaki, Kaori and Shinnakasu, Atsushi and Kawade, Shigeru and Arimura, Aiko and Hashiguchi, Hiroshi and Ogiso, Kazuma and Kamada, Tetsuro and Kurano, Mihoko and Morino, Katsutaro and Nishio, Yoshihiko},
title = {Pemafibrate is associated with greater reductions in MDA-LDL and small dense LDL fractions with exploratory PBMC gene-expression changes: a prespecified subanalysis of the PARADISE in Kagoshima study},
journal = {Frontiers in Clinical Diabetes and Healthcare},
year = {2026},
volume = {7},
doi = {10.3389/fcdhc.2026.1850470}
}
EUVIMED